1. Market Research
  2. > Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypoxic-Ischemic Encephalopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoxic-Ischemic Encephalopathy. Hypoxic-Ischemic Encephalopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypoxic-Ischemic Encephalopathy.
- A review of the Hypoxic-Ischemic Encephalopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypoxic-Ischemic Encephalopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypoxic-Ischemic Encephalopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypoxic-Ischemic Encephalopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypoxic-Ischemic Encephalopathy Overview 6
Therapeutics Development 7
Pipeline Products for Hypoxic-Ischemic Encephalopathy - Overview 7
Pipeline Products for Hypoxic-Ischemic Encephalopathy - Comparative Analysis 8
Hypoxic-Ischemic Encephalopathy - Therapeutics under Development by Companies 9
Hypoxic-Ischemic Encephalopathy - Therapeutics under Investigation by Universities/Institutes 10
Hypoxic-Ischemic Encephalopathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hypoxic-Ischemic Encephalopathy - Products under Development by Companies 15
Hypoxic-Ischemic Encephalopathy - Products under Investigation by Universities/Institutes 16
Hypoxic-Ischemic Encephalopathy - Companies Involved in Therapeutics Development 17
Chiesi Farmaceutici SpA 17
Hypoxic-Ischemic Encephalopathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Assessment by Therapeutic Class 27
Drug Profiles 29
topiramate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Cerebrolysin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
topiramate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
epoetin alfa - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
darbepoetin alfa - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Mesenchymal Stem Cells - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Caspase-2 Inhibitor - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Hypoxic-Ischemic Encephalopathy - Recent Pipeline Updates 37
Hypoxic-Ischemic Encephalopathy - Dormant Projects 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products under Development for Hypoxic-Ischemic Encephalopathy, H2 2013 7
Number of Products under Development for Hypoxic-Ischemic Encephalopathy - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Hypoxic-Ischemic Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 22
Number of Products by Stage and Route of Administration, H2 2013 24
Number of Products by Stage and Molecule Type, H2 2013 26
Number of Products by Stage and Therapeutic Class, H2 2013 28
Hypoxic-Ischemic Encephalopathy Therapeutics - Recent Pipeline Updates, H2 2013 37
Hypoxic-Ischemic Encephalopathy - Dormant Projects, H2 2013 38



List of Figures

Number of Products under Development for Hypoxic-Ischemic Encephalopathy, H2 2013 7
Number of Products under Development for Hypoxic-Ischemic Encephalopathy - Comparative Analysis, H2 2013 8
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 13
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Mechanism of Action, H2 2013 21
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 22
Number of Products by Top 10 Route of Administration, H2 2013 23
Number of Products by Stage and Top 10 Route of Administration, H2 2013 24
Number of Products by Top 10 Molecule Type, H2 2013 25
Number of Products by Stage and Top 10 Molecule Type, H2 2013 26
Number of Products by Top 10 Therapeutic Class, H2 2013 27
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 28



Companies Mentioned

Chiesi Farmaceutici SpA

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.